BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 26291150)

  • 21. A randomized controlled trial to test the efficacy of trans-tympanic injections of a sodium thiosulfate gel to prevent cisplatin-induced ototoxicity in patients with head and neck cancer.
    Rolland V; Meyer F; Guitton MJ; Bussières R; Philippon D; Bairati I; Leclerc M; Côté M
    J Otolaryngol Head Neck Surg; 2019 Jan; 48(1):4. PubMed ID: 30651130
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of severe late radiotherapy-related toxicity after hyperfractionated radiotherapy with or without concomitant cisplatin in locally advanced head and neck cancer. Secondary retrospective analysis of a randomized phase III trial (SAKK 10/94).
    Ghadjar P; Simcock M; Zimmermann F; Betz M; Bodis S; Bernier J; Studer G; Aebersold DM;
    Radiother Oncol; 2012 Aug; 104(2):213-8. PubMed ID: 22726581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Concomitant association of radiotherapy and chemotherapy (CDDP 4-6 mg/m2/daily in continuous i.v. administration) in locally advanced ORL tumors].
    Bachaud JM; Albin N; Gay C; Chatelut E; Benchalal M; David JM; Boneu A; Serrano E; Canal P; Daly-Schveitzer N
    Bull Cancer; 1994 Mar; 81(3):212-8. PubMed ID: 7894129
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Age-corrected hearing loss after chemoradiation in cervical cancer patients.
    Marnitz S; Schermeyer L; Dommerich S; Köhler C; Olze H; Budach V; Martus P
    Strahlenther Onkol; 2018 Nov; 194(11):1039-1048. PubMed ID: 30120496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hearing loss due to concurrent daily low-dose cisplatin chemoradiation for locally advanced head and neck cancer.
    Zuur CL; Simis YJ; Verkaik RS; Schornagel JH; Balm AJ; Dreschler WA; Rasch CR
    Radiother Oncol; 2008 Oct; 89(1):38-43. PubMed ID: 18706728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sensorineural hearing loss in patients with head and neck cancer after chemoradiotherapy and radiotherapy: a systematic review of the literature.
    Theunissen EA; Bosma SC; Zuur CL; Spijker R; van der Baan S; Dreschler WA; de Boer JP; Balm AJ; Rasch CR
    Head Neck; 2015 Feb; 37(2):281-92. PubMed ID: 24478269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Concomitant weekly cisplatin and radiotherapy for head and neck cancer.
    Homma A; Inamura N; Oridate N; Suzuki S; Hatakeyama H; Mizumachi T; Kano S; Sakashita T; Onimaru R; Yasuda K; Shirato H; Fukuda S
    Jpn J Clin Oncol; 2011 Aug; 41(8):980-6. PubMed ID: 21715362
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II feasibility trial of adjuvant chemoradiotherapy with 3-weekly cisplatin for Japanese patients with post-operative high-risk squamous cell carcinoma of the head and neck.
    Kiyota N; Tahara M; Okano S; Kawashima M; Matsuura K; Onozawa Y; Nibu K; Hayashi R; Yoshimura K; Ohtsu A
    Jpn J Clin Oncol; 2012 Oct; 42(10):927-33. PubMed ID: 22923484
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose intra-arterial cisplatin therapy followed by radiation therapy for advanced squamous cell carcinoma of the head and neck.
    Wilson WR; Siegel RS; Harisiadis LA; Davis DO; Nguyen HH; Bank WO
    Arch Otolaryngol Head Neck Surg; 2001 Jul; 127(7):809-12. PubMed ID: 11448355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short-term cohort study on sensorineural hearing changes in head and neck radiotherapy.
    Cheraghi S; Nikoofar P; Fadavi P; Bakhshandeh M; Khoie S; Gharehbagh EJ; Farahani S; Mohebbi A; Vasheghani M; Zare M; Nikoofar A; Mahdavi SR
    Med Oncol; 2015 Jul; 32(7):200. PubMed ID: 26071124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cochlea CT radiomics predicts chemoradiotherapy induced sensorineural hearing loss in head and neck cancer patients: A machine learning and multi-variable modelling study.
    Abdollahi H; Mostafaei S; Cheraghi S; Shiri I; Rabi Mahdavi S; Kazemnejad A
    Phys Med; 2018 Jan; 45():192-197. PubMed ID: 29329660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decreased hearing after combined modality therapy for head and neck cancer.
    Pearson SE; Meyer AC; Adams GL; Ondrey FG
    Am J Otolaryngol; 2006; 27(2):76-80. PubMed ID: 16500467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of acute toxicity grade ≥ 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin.
    Uyterlinde W; Belderbos J; Baas C; van Werkhoven E; Knegjens J; Baas P; Smit A; Rikers C; van den Heuvel M
    Clin Lung Cancer; 2013 Sep; 14(5):541-8. PubMed ID: 23835165
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hearing Loss After Cisplatin-based Chemoradiotherapy for Locally Advanced Head and Neck Cancer: A Prospective Single-institution Study.
    Musio D; DE Vincentiis M; D'Urso P; Musacchio A; Maiuri V; Zaccaro L; Ralli M; Marchetti C; Turchetta R; Tombolini V; DE Felice F
    Anticancer Res; 2022 Jun; 42(6):3003-3009. PubMed ID: 35641273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of radiation and chemoradiation-induced sensorineural hearing loss in head and neck cancer patients.
    Mahdavi SR; Rezaeyan A; Nikoofar A; Bakhshandeh M; Farahani S; Cheraghi S
    J Cancer Res Ther; 2020; 16(3):539-545. PubMed ID: 32719264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Audiometric patterns in ototoxicity of intra-arterial Cisplatin chemoradiation in patients with locally advanced head and neck cancer.
    Zuur CL; Simis YJ; Lansdaal PE; Rasch CR; Tange RA; Balm AJ; Dreschler WA
    Audiol Neurootol; 2006; 11(5):318-30. PubMed ID: 16983183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Statistical model for prediction of hearing loss in patients receiving cisplatin chemotherapy.
    Johnson A; Tarima S; Wong S; Friedland DR; Runge CL
    JAMA Otolaryngol Head Neck Surg; 2013 Mar; 139(3):256-64. PubMed ID: 23429908
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hearing loss after radiotherapy for pediatric brain tumors: effect of cochlear dose.
    Hua C; Bass JK; Khan R; Kun LE; Merchant TE
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):892-9. PubMed ID: 18395355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between hematotoxicity and serum albumin level in the treatment of head and neck cancers with concurrent chemoradiotherapy using cisplatin.
    Ishizuka M; Fujimoto Y; Itoh Y; Kitagawa K; Sano M; Miyagawa Y; Ando A; Hiramatsu M; Hirasawa N; Ishihara S; Nakashima T; Yamada K
    Jpn J Clin Oncol; 2011 Aug; 41(8):973-9. PubMed ID: 21693483
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gamma knife radiosurgery for vestibular schwannoma: early hearing outcomes and evaluation of the cochlear dose.
    Lasak JM; Klish D; Kryzer TC; Hearn C; Gorecki JP; Rine GP
    Otol Neurotol; 2008 Dec; 29(8):1179-86. PubMed ID: 18931646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.